J
2.85
0.00 (0.00%)
| Previous Close | 2.85 |
| Open | 2.83 |
| Volume | 119,056 |
| Avg. Volume (3M) | 662,172 |
| Market Cap | 46,321,904 |
| Price / Book | 1.77 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -5.27 |
| Total Debt/Equity (MRQ) | 6.13% |
| Current Ratio (MRQ) | 4.31 |
| Operating Cash Flow (TTM) | -69.71 M |
| Levered Free Cash Flow (TTM) | -43.72 M |
| Return on Assets (TTM) | -56.50% |
| Return on Equity (TTM) | -101.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Jasper Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.27% |
| % Held by Institutions | 87.94% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (UBS, 777.19%) | Buy |
| Median | 20.00 (601.75%) | |
| Low | 4.00 (BMO Capital, 40.35%) | Hold |
| Average | 16.83 (490.53%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 3.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 15 Aug 2025 | 25.00 (777.19%) | Buy | 3.11 |
| BMO Capital | 08 Jul 2025 | 4.00 (40.35%) | Hold | 3.02 |
| Evercore ISI Group | 08 Jul 2025 | 20.00 (601.75%) | Buy | 3.02 |
| JMP Securities | 08 Jul 2025 | 12.00 (321.05%) | Buy | 3.02 |
| BTIG | 07 Jul 2025 | 20.00 (601.75%) | Buy | 3.04 |
| HC Wainwright & Co. | 07 Jul 2025 | 20.00 (601.75%) | Buy | 3.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Jasper Therapeutics to Present at Upcoming Investor Conferences |
| 13 Aug 2025 | Announcement | Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 09 Jul 2025 | Announcement | Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway |
| 07 Jul 2025 | Announcement | Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |